Glukoza Hztm (Glucose, Anhydrous)

Glukoza Hztm is indicated for situations where rapid glucose supplementation is required.

• Treatment of acute hypoglycemia in patients unable to take oral glucose.
• Energy supplementation during short‑term fasting or pre‑operative preparation.
• Component of total parenteral nutrition regimens for patients unable to receive enteral feeding.
• Support for metabolic needs during critical illness or severe trauma.
• Adjunct in electrolyte‑balanced solutions for intravenous therapy.

When administered intravenously, Glukoza Hztm may be associated with a range of observed effects.

Common

• Transient hyperglycemia.
• Mild nausea or vomiting.
• Local irritation at the injection site.
• Temporary electrolyte shifts, particularly potassium.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Hypersensitivity reactions such as rash, itching, or anaphylaxis.
• Fluid overload in patients with compromised cardiac function.
• Hyperosmolar coma in extreme cases.

Safe use of Glukoza Hztm requires attention to patient condition and clinical context.

• Assess blood glucose levels before and during infusion.
• Adjust dose in patients with renal or hepatic impairment.
• Monitor for signs of fluid overload, especially in heart failure.
• Use caution in diabetic patients to avoid excessive glucose spikes.
• Avoid rapid infusion rates that may cause osmotic shifts.
• Ensure compatible IV fluids; incompatibility may cause precipitation.
• Discontinue if hypersensitivity develops.

Glukoza Hztm can interact with other intravenous agents and systemic medications.

Avoid

• Concurrent high‑dose insulin therapy without glucose monitoring.
• Co‑administration with other hypertonic dextrose solutions.

Use with caution

• Loop diuretics that may alter electrolyte balance.
• Catecholamine vasopressors that affect glucose metabolism.
• Steroids or thiazide diuretics that raise blood glucose.
• Total parenteral nutrition mixtures containing other carbohydrates.